Survival from non-stage 4 neuroblastoma without cytotoxic therapy: An analysis of clinical and biological markers

European Journal of Cancer

Volumn 33, Issue 12, 1997, Pages 2117-2120

  Cheung, N K V ^a   Kushner, B H ^a   Laquaglia, M P ^a   Kramer, K ^a   Ambros, P ^b   Ambros, I ^b   Ladanyi, M ^c   Eddy, J ^a   Bonilla, M A ^a   Gerald, W ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

^c NONE   (United States)

Author keywords

45; CD44; Diploidy; Local regional; MYCN; Neuroblastoma; Progression histopathology; trk A

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; HERMES ANTIGEN; NEUROTROPHIN RECEPTOR; TECHNETIUM 99M; TYROSINE KINASE RECEPTOR;

ANTIGEN EXPRESSION; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONFERENCE PAPER; DIPLOIDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFANT; MALE; NEUROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0031409339     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)00281-5     Document Type: Conference Paper

References (26)

1. Brodeur GM, Castleberry RP. Neuroblastoma. In Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology, 3rd edn, chapter 29, J.B. Lippincott Company, Philadelphia, 1996.
2. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985, 313, 1111-1116.
3. Rubie H, Plantz D, Michon J, et al. Localized neuroblastoma: N-myc gene amplification is the main prognostic factor and post-operative treatment can be deleted in infants. Med Pediatr Oncol 1993, 21, 582.
4. Nakagawara N, Nakagawara A, Scavarda NJ, et al. High expression of the TRK gene in human neuroblastoma is associated with favorable outcome: possible role in tumor differentiation and regression. N Engl J Med 1993, 328, 847-854.
5. Suzuki T., Bogenmann E., Shimada H., Stram D., Seeger R. C. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. J Natl Cancer Inst. 85:1993;377-384.
6. Hayashi Y, Kanda N, Inaba T, et al. Cytogenetic findings and prognosis in neuroblastoma with emphasis on marker chromosome 1. Cancer 1989, 63, 126-132.
7. Fong C, White PS, Peterson K, et al. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res 1992, 52, 1780-1785.
8. Caron H, Van Sluis P, De Kraker J, et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. N Engl J Med 1996, 334, 225-230.
9. Norris MD, Bordow SB, Marshall GM, et al. Expression of the gene for multidrug-resistance-associated protein and outcome in patients with neuroblastoma. N Engl J Med 1996, 334, 231-238.
10. Look AT, Hayes FA, Nitschke R, et al. Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma. N Engl J Med 1984, 311, 231-235.
11. Bowman L, Castleberry R, Altschuler G, et al. Therapy based on DNA index (DI) for infants with unresectable and disseminated neuroblastoma (NB): the Pediatric Oncology Group "better risk" study. Proc Am Soc Clin Oncol 1992, 11, 365.
12. Kushner BH, Cheung NKV, LaQuaglia MP, et al. Survival from locally invasive or metastatic neuroblastoma without cytotoxic therapy. J Clin Oncol 1996, 14, 373-381.
13. Brodeur G, Seeger RC, Barrett A, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol 1988, 6, 1874-1881.
14. Brodeur G, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol 1993, 11, 1466-1477.
15. Kushner BH, LaQuaglia MP, Bonilla MA, et al. Highly effective induction therapy for stage 4 neuroblastoma in children over one year of age. J Clin Oncol 1994, 12, 2607-2613.
16. Stock C, Ambros IM, Mann G, et al. Detection of 1p36 deletions in paraffin sections of neuroblastoma tissues. Genes Chrom Cancer 1993, 6, 1-9.
17. Favrot M. C., Combaret V., Lasset C. CD44 - a new prognostic marker for neuroblastoma. N Engl J Med. 329:1993;1965.
18. Kramer K., Gerald W., LeSauteur L., Saragovi H. U., Cheung N. K. C. Prognostic value of TrkA protein detection by monoclonal antibody 5C3 in neuroblastoma. Clinical Cancer Research. 2:1996;1361-1367.
19. Knudson A. G. J., Meadows A. T. Regression of neuroblastoma IV-s: a genetic hypothesis. N Engl J Med. 302:1990;1254-1256.
20. Busque L, Zhu J, DeHart D, et al. An expression based clonality assay at the human androgen receptor locus (HUMARA) on chromosome X. Nucleic Acids Res 1994, 22, 697-698.
21. Bourhis J, Dominici C, McDowell H, et al. N-myc genomic content and DNA ploidy in stage IVS neuroblastoma. J Clin Oncol 1991, 9, 1371-1375.
22. De Bernardi B, Pianca C, Boni L, et al. Disseminated Neuroblastoma (Stage IV and IV-S) in the first year of life. Cancer 1992, 70, 1625-1633.
23. Cohn SL, Look AT, Joshi VV, et al. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group Study. Cancer Res 1995, 55, 721-726.
24. Fabbretti G, Valenti C, Loda M, et al. N-myc gene amplification/expression in localized stroma-rich neuroblastoma (ganglioneuroblastoma) Hum Pathol 1993, 24, 294-297.
25. Philip T. Overview of current treatment of neuroblastoma. Am J Pediatr Hematol/Oncol. 14:1992;97-102.
26. Meadows A. T. Curing cancer in children: minimizing price, maximizing value. J Clin Oncol. 13:1995;1837-1839.